| 摘要: |
| ［摘要］ 目的 对比非肌层浸润性膀胱癌（NMIBC）经尿道膀胱肿瘤切除术（TURBT）后膀胱灌注羟喜树碱和吡柔比星的疗效和安全性。方法 选择该院2012-01～2015-12收治的膀胱癌患者76例，采用随机数字表法将TURBT术后的NMIBC患者分为羟喜树碱组和吡柔比星组，各38例，于术后1周进行膀胱灌注化疗，比较两组复发率、不良反应发生率以及化疗费用。结果 随访时间12～60个月，羟喜树碱组1年内复发率高于吡柔比星组（P<0.05），但两组2年内、5年内复发率差异无统计学意义(P>0.05)。吡柔比星组灌注后膀胱刺激征发生率高于羟喜树碱组（P<0.05）。结论 羟喜树碱和吡柔比星均可有效预防NMIBC术后复发，吡柔比星对预防术后短期内复发疗效较好，但不良反应多且价格较贵，而羟喜树碱不良反应少且价格有优势。 |
| 关键词: 非肌层浸润性膀胱癌 膀胱灌注化疗 羟喜树碱 吡柔比星 |
| DOI：10.3969/j.issn.1674-3806.2017.05.14 |
| 分类号:R 737.14 |
| 基金项目: |
|
| Clinical effects of different intravesical instillation chemotherapies on non-muscle invasive bladder cancer after transurethral electroresection |
|
LONG Jun, LIN Hai-song, MO Zeng-nan, et al
|
|
Department of Urology and Nephrology,the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Objective To compare the efficacy and safety between intravesical instillation chemotherapy by hydroxycamptothecin and by pirarubicin for treatment of the recurrence of bladder cancer after transurethral resection of non-muscle invasive bladder cancer(NMIBC).Methods Seventy-six patients with non-muscle invasive bladder cancer were divided into the hydroxycamptothecin group(n=38) and the pirarubicin group(n=38) by random number table. The hydroxycamptothecin group received regular intravesical instillation of hydroxycamptothecin and the pirarubicin group received regular intravesical instillation of pirarubicin one week after transurethral resection of bladder cancer. The recurrence rate of bladder cancer, adverse reactions and the costs of chemotherapy were compared between the two groups.Results The patients received a follow-up of 12～60 months.The one-year-recurrence rate of the hydroxycamptothecin group was higher than that of the pirarubicin group(P<0.05), but there was no significant difference in the total recurrence rate between the two groups after a follow-up of 12～60 months(P>0.05). The incidence of bladder irritation in the hydroxycamptothecin group was lower than that in the pirarubiein group(P<0.05).Conclusion Both hydroxycamptothecin and pirarubicin can be effective in preventing postoperative recurrence of NMIBC. Compared with hydroxycamptothecin, pirarubicin has a better short-term curative effect, but a higher incidence of adverse reactions and higher costs. |
| Key words: Non-muscle invasive bladder cancer Intravesical instillation chemotherapy Hydroxycamptothecin Pirarubicin |
